The Schall Law Firm has initiated a securities litigation effort against Inovio Pharmaceuticals, Inc., inviting investors to join a class action lawsuit alleging material misrepresentations regarding the company's manufacturing capabilities and regulatory timeline projections.
The lawsuit centers on claims that Inovio made false or misleading statements concerning deficiencies in its CELLECTRA device manufacturing processes and the feasibility of submitting a Biologics License Application for INO-3107 by the second half of 2024. Securities purchased between October 10, 2023 and December 26, 2025 fall within the class period for the alleged misconduct.
Investors seeking to participate in the litigation must act before the April 7, 2026 deadline. The Schall Law Firm is accepting inquiries from shareholders who believe they suffered losses as a result of the company's alleged disclosures or omissions during the specified timeframe.